Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'BEZAFIBRATE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 184 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bonilla, S; Redonnet, A; Noel-Suberville, C; Groubet, R; Pallet, V; Higueret, P
      Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver

      JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
    2. Bonilla, S; Redonnet, A; Noel-Suberville, C; Groubet, R; Pallet, V; Higueret, P
      Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver

      JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
    3. Kagawa, H; Nomura, S; Nagahama, M; Ozaki, Y; Fukuhara, S
      Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    4. de Barrio, M; Matheu, V; Baeza, ML; Tornero, P; Rubio, M; Zubeldia, JM
      Bezafibrate-induced anaphylactic shock: Unusual clinical presentation

      JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY
    5. Ohmichi, M; Ikegami, H; Kurachi, H; Node, K; Morishige, K; Nishio, Y; Adachi, K; Matumoto, K; Hayakawa, J; Tasaka, K; Azuma, C; Murata, Y
      Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy

      MATURITAS
    6. Lipscombe, J; Lewis, GF; Cattran, D; Bargman, JM
      Deterioration in renal function associated with fibrate therapy

      CLINICAL NEPHROLOGY
    7. Vasquez, M; Roglans, N; Cabrero, A; Rodriguez, C; Adzet, T; Alegret, M; Sanchez, RM; Laguna, JC
      Benzafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue

      MOLECULAR AND CELLULAR BIOCHEMISTRY
    8. Mattu, M; Vannini, A; Coletta, M; Fasano, M; Ascenzi, P
      Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study

      JOURNAL OF INORGANIC BIOCHEMISTRY
    9. Meco, JF; Vila, R; Pujol, R; Bros, R; Domenech, P; Fiol, C; Pinto, X
      Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    10. Suzuki, Y; Urano, T; Ihara, H; Nakajima, T; Nagai, N; Takada, Y; Taminato, T; Takada, A
      Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in HepG2 cells

      LIFE SCIENCES
    11. Dierkes, J; Westphal, S; Kunstmann, S; Banditt, P; Lossner, A; Luley, C
      Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

      ATHEROSCLEROSIS
    12. Karpe, F; Taskinen, MR; Nieminen, MS; Frick, MH; Kesaniemi, YA; Pasternack, A; Hamsten, A; Syvanne, M
      Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment

      ATHEROSCLEROSIS
    13. Yoshikawa, H; Tajiri, Y; Sako, Y; Hashimoto, T; Umeda, F; Nawata, H
      Effects of bezafibrate on beta-cell function of rat pancreatic islets

      EUROPEAN JOURNAL OF PHARMACOLOGY
    14. Rodriguez, C; Cabrero, A; Roglans, N; Adzet, T; Sanchez, RM; Vazquez, M; Ciudad, CJ; Laguna, JC
      Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells

      BIOCHEMICAL PHARMACOLOGY
    15. Brown, WV
      Novel approaches to lipid lowering: What is on the horizon?

      AMERICAN JOURNAL OF CARDIOLOGY
    16. Rustemeijer, C; Schouten, JA; Voerman, HJ; Hensgens, HESJ; Donker, AJM; Heine, RJ
      Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

      DIABETES-METABOLISM RESEARCH AND REVIEWS
    17. Dergunov, AD; Smirnova, EA; Merched, A; Visvikis, S; Siest, G; Yakushkin, VV; Tsibulsky, V
      Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    18. Paragh, G; Balogh, Z; Seres, I; Harangi, M; Boda, J; Kovacs, P
      Effect of gemfibrozil on HDL-Associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia

      CLINICAL DRUG INVESTIGATION
    19. de Man, FHAF; Jonkers, IJAM; Schwedhelm, E; Smelt, AHM; Onkenhout, W; van Duyvenvoorde, W; Buytenhek, R; Leuven, JAG; Troost, R; van der Laarse, A; Princen, HMG
      Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia - Effects of bezafibrate therapy

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    20. Faergeman, O
      Hypertriglyceridemia and the fibrate trials

      CURRENT OPINION IN LIPIDOLOGY
    21. Hernandez-Mijares, A; Lluch, I; Vizcarra, E; Martinez-Triguero, ML; Ascaso, JF; Carmena, R
      Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects

      NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
    22. Kozak, W; Kluger, MJ; Kozak, A; Wachulec, M; Dokladny, K
      Role of cytochrome P-450 in endogenous antipyresis

      AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
    23. Gorski, J; Zendzian-Piotrowska, M; Wolfrum, C; Nawrocki, A; Spener, F
      Effect of sex and bezafibrate on incorporation of blood borne palmitate into lipids of rat liver nuclei

      MOLECULAR AND CELLULAR BIOCHEMISTRY
    24. Honeck, H; Gross, V; Erdmann, B; Kargel, E; Neunaber, R; Milia, AF; Schneider, W; Luft, FC; Schunck, WH
      Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice

      HYPERTENSION
    25. Miyaguchi, S; Ebinuma, H; Imaeda, H; Nitta, Y; Watanabe, T; Saito, H; Ishii, H
      A novel treatment for refractory primary biliary cirrhosis?

      HEPATO-GASTROENTEROLOGY
    26. Spieker, LE; Noll, G; Hannak, M; Luscher, TF
      Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    27. Brites, FD; Fernandez, KM; Yael, MJ; Wikinski, RLW
      Evolution of a patient with a partial deficiency of lecithin : cholesterolacyltransferase

      MEDICINA-BUENOS AIRES
    28. Karbowska, J; Kochan, Z; Swierczynski, J
      Differential effect of clofibrate on acetyl-CoA carboxylase mRNA level in rat white and brown adipose tissue

      LIFE SCIENCES
    29. Lomnicky, Y; Haimov, T; Luria, MH; Friedman, M; Hoffman, A
      Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration

      JOURNAL OF PHARMACEUTICAL SCIENCES
    30. Lawrence, JW; Kroll, DJ; Eacho, PI
      Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus

      JOURNAL OF LIPID RESEARCH
    31. Marrapodi, M; Chiang, JYL
      Peroxisome proliferator-activated receptor alpha (PPAR alpha) and agonist inhibit cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription

      JOURNAL OF LIPID RESEARCH
    32. Autran, D; Attia, N; Dedecjus, M; Durlach, V; Girard-Globa, A
      Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment

      ATHEROSCLEROSIS
    33. Stalenhoef, AFH; de Graaf, J; Wittekoek, ME; Bredie, SJH; Demacker, PNM; Kastelein, JJP
      The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia

      ATHEROSCLEROSIS
    34. Totsuka, M; Miyashita, Y; Ito, Y; Watanabe, H; Murano, T; Shirai, K
      Enhancement of preheparin serum lipoprotein lipase mass by bezafbirate administration

      ATHEROSCLEROSIS
    35. de Man, FH; Nieuwland, R; van der Laarse, A; Romijn, F; Smelt, AHM; Leuven, JAG; Sturk, A
      Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy

      ATHEROSCLEROSIS
    36. Pauciullo, P; Borgnino, C; Paoletti, R; Mariani, M; Mancini, M
      Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

      ATHEROSCLEROSIS
    37. Marcello, S; Gladstein, J; Tesone, P; Mas, R
      Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    38. Hirano, T; Kazumi, T; Yoshino, G
      Long-term efficacy of bezafibrate in reduction of small, dense low-densitylipoprotein by hypotriglyceridemic action

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    39. Kurihara, T; Furukawa, M; Tsuchiya, M; Akimoto, M; Ishiguro, H; Hashimoto, H; Niimi, A; Maeda, A; Shigemoto, M; Yamasha, K
      Effect of bezafibrate in the treatment of primary biliary cirrhosis

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    40. Schlesinger, Z; Vered, Z; Friedenson, A; Reisin, L; Jafari, J; Flieb, T; Sclarovsky, S; Friedman, Y; Ostfeld, B; Solodky, A; Abinader, E; Rochfleish, S; Palant, A; Schneider, H; Rosenfeld, T; Khalid, S; Wolfson, E; Kishon, Y; Narinsky, R; Rotzak, R; Davidov, A; Levine, G; Zahavi, I; Vitrai, J; Diker, D; Pelled, B; Pardu, J; Galamidi, J; Majadla, R; Laniado, S; Sherf, L; Braun, S; Eschar, Y; Caspi, A; Arditi, A; Botwin, S; Arkavi, L; Ziv, M; David, D; Weisenberg, D; Kohanovski, M; Meisel, S; Rougin, N; Yahalom, M; Glusman-Vazan, A; Markiewitz, W; Motlak, D; Lessick, J; Kagan, G; Marmour, A; Flich, M; Solomon, R; Tzivoni, D; Zion, M; Balkin, J; Rabinowitz, B; Barasch, E; Brill, Z; Aharon, L; Asman, A; Battler, A; Gueron, M; Cristal, N; Liel, N; Tsatskis, B; Henkin, J
      Secondary prevention by raising HDL cholesterol and reducing triglyceridesin patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study

      CIRCULATION
    41. Cabrero, A; Alegret, M; Sanchez, R; Adzet, T; Laguna, JC; Vazquez, M
      Peroxisome proliferator-activated receptor alpha (PPAR alpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    42. Feher, MD; Caslake, M; Foxton, J; Cox, A; Packard, CJ
      Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate

      DIABETES-METABOLISM RESEARCH AND REVIEWS
    43. Wolfrum, C; Buhlmann, C; Rolf, B; Borchers, T; Spener, F
      Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    44. Iwasaki, S; Tsuda, K; Ueta, H; Aono, R; Ono, M; Saibara, T; Maeda, T; Onishi, S
      Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis

      HEPATOLOGY RESEARCH
    45. Scatena, R; Nocca, G; De Sole, P; Rumi, C; Puggioni, P; Remiddi, F; Bottoni, P; Ficarra, S; Giardina, B
      Bezafibrate as differentiating factor of human myeloid leukemia cells

      CELL DEATH AND DIFFERENTIATION
    46. Krobot, KJ; Wenke, K; Reichart, B
      Simvastatin after orthotopic heart transplantation - Costs and consequences

      PHARMACOECONOMICS
    47. Hoffman, A; Lomnicky, Y; Luria, MH; Gilhar, D; Friedman, M
      Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained releasepreparation of the drug

      PHARMACEUTICAL RESEARCH
    48. Meyer, K; Volkl, A; Endele, R; Kuhnle, HF; Pill, J
      Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPAR alpha)

      ARCHIVES OF TOXICOLOGY
    49. Beggs, PW; Clark, DWJ; Williams, SM; Coulter, DM
      A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP)

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    50. Mooney, A
      Treating patients with hypertriglyceridaemia saves lives: Triglyceride revisited

      CURRENT MEDICAL RESEARCH AND OPINION
    51. Kawamura, I; Yamamoto, N; Sakai, F; Yamazaki, H; Goto, T
      Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice

      ANTICANCER RESEARCH
    52. Hottelart, C; El Esper, N; Achard, JM; Pruna, A; Fournier, A
      Fenofibrate increases creatininemia but does not alter glomerular filtration rate in patients with mild renal insufficiency

      NEPHROLOGIE
    53. Papadakis, JA; Ganotakis, ES; Jagroop, IA; Winder, AF; Mikhailidis, DP
      Statin plus fibrate combination therapy - Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    54. Hunninghake, DB
      Pharmacologic management of triglycerides

      CLINICAL CARDIOLOGY
    55. Ou, JF; Saku, K; Jimi, S; Liao, YL; Ohta, T; Zhang, B; Arakawa, K
      Combined effects of probucol and bezafibrate on lipoprotein metabolism andliver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits

      JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION
    56. Brown, PJ; Winegar, DA; Plunket, KD; Moore, LB; Lewis, MC; Wilson, JG; Sundseth, SS; Koble, CS; Wu, ZD; Chapman, JM; Lehmann, JM; Kliewer, SA; Willson, TM
      A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity

      JOURNAL OF MEDICINAL CHEMISTRY
    57. Otto, C; Schwandt, P
      When statins are not enough to lower lipid levels - Benefits and risks of lipid-lowering combination therapy, especially the combination statin and fibrate

      INTERNIST
    58. Karbowska, J; Kochan, Z; Zelewski, L; Swierczynski, J
      Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression

      EUROPEAN JOURNAL OF PHARMACOLOGY
    59. VANCE DE; WALKEY CJ
      ROLES FOR THE METHYLATION OF PHOSPHATIDYLETHANOLAMINE

      Current opinion in lipidology
    60. SIAMOPOULOS KC; ELISAF M; KATOPODIS K
      IATROGENIC HYPERKALEMIA - POINTS TO CONSIDER IN DIAGNOSIS AND MANAGEMENT

      Nephrology, dialysis, transplantation
    61. AGRAWAL B; KOPECKY J; KRANZLIN B; ROHMEISS P; PILL J; GRETZ N
      ACUTE EFFECTS OF BEZAFIBRATE ON BLOOD-PRESSURE AND RENAL HEMODYNAMICSIN SHR AND WKY RATS

      Nephrology, dialysis, transplantation
    62. HAYASHI K; KURUSHIMA H; KUGA Y; SHINGU T; TANAKA K; YASUNOBU Y; NOMURA K; OHTANI H; HIRAGA T; TOYOTA Y; KATANO T; SAKAIOHTA K; KAJIYAMA G
      COMPARISON OF THE EFFECT OF BEZAFIBRATE ON IMPROVEMENT OF ATHEROGENICLIPOPROTEINS IN JAPANESE FAMILIAL COMBINED HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT IMPAIRED GLUCOSE-TOLERANCE

      Cardiovascular drugs and therapy
    63. GOTO H; YAMASHITA S; MAKITA T
      PREVENTION OF OROTIC-ACID-INDUCED FATTY LIVER IN MALE RATS BY DEHYDROEPIANDROSTERONE AND OR PHENOBARBITAL/

      Journal of veterinary medical science
    64. NEUMAN MP; NEUMAN FJ; NEUMAN J; ROCCELLA MC; MONTENERO Y; BRUETMAN JE; GONZALEZ C
      EFFECT OF BEZAFIBRATE ON LIPID-PEROXIDATION IN PATIENTS WITH HYPERTRIGLYCERIDEMIA

      Advances in therapy
    65. Mikhailidis, DP; Ganotakis, ES; Spyropoulos, KA; Jagroop, IA; Byrne, DJ; Winder, AF
      Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice

      INTERNATIONAL ANGIOLOGY
    66. MURAKAMI T; NAGAMURA Y; HIRANO K
      ETHANOLAMINE STIMULATES REPAIR PROCESSES IN ACUTE CCL4 DAMAGE OF MOUSE-LIVER

      Toxicology letters
    67. MONTALESCOT G; COLLET JP; CHOUSSAT R; THOMAS D
      FIBRINOGEN AS A RISK FACTOR FOR CORONARY HEART-DISEASE

      European heart journal
    68. ERICSSON CG
      RESULTS OF THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND AN UPDATE ON TRIALS NOW IN PROGRESS

      European heart journal
    69. GOLDBOURT U; BRUNNER D; BEHAR S; REICHERREISS H
      BASE-LINE CHARACTERISTICS OF PATIENTS PARTICIPATING IN THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY - THE BIP (BEZAFIBRATE INFARCTION PREVENTION) STUDY-GROUP

      European heart journal
    70. Susekov, AV; Tvorogova, MG; Arabidze, GG; Kukharchuk, VV
      Lipanor treatment of atherogenic hyperlipoproteinemia

      TERAPEVTICHESKII ARKHIV
    71. Vazquez-Chavez, C; Salinas-Orozco, S; Gomez-Diaz, RA; Rosso-Juarez, MM; Moreno-Vazquez, K; Nissen-Torres, T; Arguero-Sanchez, R
      Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia

      REVISTA DE INVESTIGACION CLINICA
    72. JOVINGE S; HAMSTEN A; TORNVALL P; PROUDLER A; BAVENHOLM P; ERICSSON CG; GODSLAND I; DEFAIRE U; NILSSON J
      EVIDENCE FOR A ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA IN DISTURBANCES OFTRIGLYCERIDE AND GLUCOSE-METABOLISM PREDISPOSING TO CORONARY HEART-DISEASE

      Metabolism, clinical and experimental
    73. INOUE I; NOJI S; AWATA T; TAKAHASHI K; NAKAJIMA T; SONODA M; KOMODA T; KATAYAMA S
      BEZAFIBRATE HAS AN ANTIOXIDANT EFFECT - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA IS ASSOCIATED WITH CU2-DISMUTASE IN THE LIVER(, ZN2+ SUPEROXIDE)

      Life sciences
    74. SUZUKI R; SURUGA K; GODA T; TAKASE S
      PEROXISOME PROLIFERATOR ENHANCES GENE-EXPRESSION OF CELLULAR RETINOL-BINDING PROTEIN, TYPE-II IN CACO-2 CELLS

      Life sciences
    75. Lomnicky, Y; Friedman, M; Luria, MH; Raz, I; Hoffman, A
      The effect of the mode of administration on the hypolipidaemic activity ofniacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats

      JOURNAL OF PHARMACY AND PHARMACOLOGY
    76. DURRINGTON PN; MACKNESS MI; BHATNAGAR D; JULIER K; PRAIS H; ARROL S; MORGAN J; WOOD GNI
      EFFECTS OF 2 DIFFERENT FIBRIC ACID-DERIVATIVES ON LIPOPROTEINS, CHOLESTERYL ESTER TRANSFER, FIBRINOGEN, PLASMINOGEN-ACTIVATOR INHIBITOR ANDPARAOXONASE ACTIVITY IN TYPE IIB HYPERLIPOPROTEINEMIA

      Atherosclerosis
    77. NARUSZEWICZ M
      FROM THE HISTORY OF INVESTIGATIONS ON THE OXIDATIVE MODIFICATION OF SMALL DENSE LDL

      Atherosclerosis
    78. GAW A
      EVIDENCE BASED APPROACH FOR THE MANAGEMENT OF MIXED HYPERLIPIDEMIA

      Atherosclerosis (Amsterdam)
    79. Uchida, K; Reilly, MP; Abraham, DJ; Asakura, T
      Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits

      JAPANESE JOURNAL OF PHYSIOLOGY
    80. Anchisi, C; Fadda, AM; Maccioni, AM; Dessi, S
      Determination of bezafibrate concentration by high performance liquid-chromatography in serum of rats treated with lead nitrate

      FARMACO
    81. ALEGRET M; VERD JC; DIAZ C; HERNANDEZ G; ADZET T; SANCHEZ RM; LAGUNA JC
      EFFECT OF HYPOLIPIDEMIC DRUGS ON KEY ENZYME-ACTIVITIES RELATED TO LIPID-METABOLISM IN NORMOLIPIDEMIC RABBITS

      European journal of pharmacology
    82. BINSACK R; STEGMEIER K; DORGE L; VOLKL A
      BEZAFIBRATE DOWN-REGULATES FIBRINOGEN BIOSYNTHESIS IN HUMAN HEPATOMA HEPG2 CELLS

      European journal of clinical investigation
    83. NAKAMURA Y; OHYA Y; ONAKA U; FUJII K; ABE I; FUJISHIMA M
      INHIBITORY-ACTION OF INSULIN-SENSITIZING AGENTS ON CALCIUM CHANNELS IN SMOOTH-MUSCLE CELLS FROM RESISTANCE ARTERIES OF GUINEA-PIG

      British Journal of Pharmacology
    84. FOUCAUD L; NIOT I; KANDA T; BESNARD P
      INDIRECT DEXAMETHASONE DOWN-REGULATION OF THE LIVER FATTY-ACID-BINDING PROTEIN EXPRESSION IN RAT-LIVER

      Biochimica et biophysica acta, L. Lipids and lipid metabolism
    85. WIERZBICKI AS; LUMB PJ; CHEUNG J; CROOK MA
      FENOFIBRATE PLUS SIMVASTATIN THERAPY VERSUS SIMVASTATIN PLUS CHOLESTYRAMINE THERAPY FOR FAMILIAL HYPERCHOLESTEROLEMIA

      Quarterly Journal of Medicine
    86. GOTO D; OKIMOTO T; ONO M; SHIMOTSU H; ABE K; TSUJITA Y; KUWANO M
      UP-REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR BY GEMFIBROZIL, A HYPOLIPIDEMIC AGENT, IN HUMAN HEPATOMA-CELLS THROUGH STABILIZATION OF MESSENGER-RNA TRANSCRIPTS

      Arteriosclerosis, thrombosis, and vascular biology
    87. BAUMGART E; SCHAD A; VOLKL A; FAHIMI HD
      DETECTION OF MESSENGER-RNAS ENCODING PEROXISOMAL PROTEINS BY NONRADIOACTIVE IN-SITU HYBRIDIZATION WITH DIGOXIGENIN-LABELED CRNAS

      HISTOCHEMISTRY AND CELL BIOLOGY
    88. LAVILLE AE; SOLA R; MOTTA C; PLANA N; HERAS M; RIBALTA J; MASANA L
      PHYSICOCHEMICAL CHANGES IN HDL3 AFTER BEZAFIBRATE TREATMENT - INFLUENCE ON FREE-CHOLESTEROL EFFLUX FROM HUMAN FIBROBLASTS

      Cardiovascular drugs and therapy
    89. DEFAIRE U; ERICSSON CG; GRIP L; NILSSON J; SVANE B; HAMSTEN A
      RETARDATION OF CORONARY ATHEROSCLEROSIS - THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND OTHER ANGIOGRAPHIC TRIALS

      Cardiovascular drugs and therapy
    90. NAKAI A; NISHIKATA M; UCHIDA T; ICHIKAWA M; MATSUYAMA K
      ENHANCED MYOPATHY FOLLOWING ADMINISTRATION OF HYPOLIPIDEMIC AGENTS UNDER URETHANE ANESTHESIA

      Biological & pharmaceutical bulletin
    91. KONDO K; MAKITA T
      MORPHOMETRY OF ABNORMAL PEROXISOMES INDUCED BY WITHDRAWAL OF BEZAFIBRATE, A HYPOLIPIDEMIC DRUG IN MALE-RAT HEPATOCYTES

      Journal of veterinary medical science
    92. GOLDBERG AC
      THE IMPACT OF LIPID-LOWERING IN CORONARY-ARTERY DISEASE

      Current opinion in cardiology
    93. POIRIER H; NIOT I; DEGRACE P; MONNOT MC; BERNARD A; BESNARD P
      FATTY-ACID REGULATION OF FATTY-ACID-BINDING PROTEIN EXPRESSION IN THESMALL-INTESTINE

      American journal of physiology: Gastrointestinal and liver physiology
    94. SUGIYAMA H; YAMADA J; TAKAMA H; KODAMA Y; WATANABE T; TAGUCHI T; SUGA T
      PHOTOAFFINITY-LABELING OF PEROXISOME PROLIFERATOR BINDING-PROTEINS INRAT HEPATOCYTES - DEHYDROEPIANDROSTERONE SULFATE-BINDING AND BEZAFIBRATE-BINDING PROTEINS

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    95. YOSHINARI M; YAMAMOTO M; WAKISAKA M; IWASE M; TAKANO K; FUJISHIMA M
      EFFECT OF BEZAFIBRATE ON HYPERCOAGULABILITY ASSESSED BY FLUOROGENIC PROTHROMBIN TIME IN HYPERLIPIDEMIC PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS

      Thrombosis research
    96. BERINGER TRO
      WARFARIN POTENTIATION WITH BEZAFIBRATE

      Postgraduate medical journal
    97. INOUE I; NOJI S; SHEN MZ; TAKAHASHI K; KATAYAMA S
      THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA (PPAR-ALPHA) REGULATES THE PLASMA THIOBARBITURIC ACID-REACTIVE SUBSTANCE (TBARS) LEVEL

      Biochemical and biophysical research communications
    98. KONDO K; MAKITA T
      INHIBITION OF PEROXISOMAL DEGRADATION BY 3-METHYLADENINE (3MA) IN PRIMARY CULTURES OF RAT HEPATOCYTES

      The Anatomical record
    99. MASNATTA LD; CUNIBERTI LA; REY RH; WERBA JP
      DETERMINATION OF BEZAFIBRATE, CIPROFIBRATE AND FENOFIBRIC ACID IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical applications
    100. YAMAMOTO K; FUKUDA N; ZHANG L; SAKAI T
      ALTERED HEPATIC-METABOLISM OF FATTY-ACIDS IN RATS FED A HYPOLIPEMIC DRUG, FENOFIBRATE

      Pharmacological research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/21 alle ore 12:41:46